TESARO (NASDAQ: TSRO) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.
Earnings & Valuation
This table compares TESARO and Corbus Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|TESARO||$223.33 million||14.25||-$496.12 million||($9.19)||-6.35|
|Corbus Pharmaceuticals||$2.44 million||146.81||-$32.42 million||($0.65)||-9.65|
This is a breakdown of recent recommendations and price targets for TESARO and Corbus Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TESARO currently has a consensus price target of $131.43, suggesting a potential upside of 125.37%. Corbus Pharmaceuticals has a consensus price target of $25.75, suggesting a potential upside of 310.69%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than TESARO.
This table compares TESARO and Corbus Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
37.0% of Corbus Pharmaceuticals shares are owned by institutional investors. 34.6% of TESARO shares are owned by insiders. Comparatively, 11.9% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility & Risk
TESARO has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500.
Corbus Pharmaceuticals beats TESARO on 9 of the 14 factors compared between the two stocks.
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company’s product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.